Endocyte (ECYT) Sees Early Activity Again Following EC145 Agreement
Tweet
Share
E-mailGet Alerts ECYT Hot Sheet
Join SI Premium – FREE
Endocyte, Inc. (Nasdaq: ECYT) shares are out of the gate higher again Tuesday, following a near 100-percent jump Monday morning.
Monday, Endocyte entered a commercialization and development agreement with Merck for Phase III EC145.
Volume is heavy early in the session, with implied volatility about 6 percent above normal. Option contract volume is also about 3 times better than the trailing 10-day average.
Overall, the stock is up 7.7 percent early.
Monday, Endocyte entered a commercialization and development agreement with Merck for Phase III EC145.
Volume is heavy early in the session, with implied volatility about 6 percent above normal. Option contract volume is also about 3 times better than the trailing 10-day average.
Overall, the stock is up 7.7 percent early.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Autodesk (ADSK) call put ratio 1.4 calls to 1 puts into quarter results
- GAP (GAP) call put ratio 3.5 calls to 1 put into quarter results
- IREN Limited (IREN) call put ratio 3.4 calls to 1 put into quarter results
Create E-mail Alert Related Categories
Momentum Movers, Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
